The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

Eligibility Criteria

• * Female, post-menopausal
• * Probable AD or MCI due to AD according to NIA-AA criteria
• * Taking a stable dose of a cholinesterase inhibitor such as donepezil/Aricept and dosage likely to remain stable throughout the trial
• * MOCA \> 11 or blind MOCA \> 8 (inclusive) at screening visit
• * Hachinski score \<5 supporting clinical judgment that dementia is not of vascular origin
• * Fluent in English
• * has a study partner / caregiver who interacts with the subject for at least 5 hours per week on average and can participate in evaluations
• * Presence based on exam, history or MRI of significant brain disease other than AD such as schizophrenia, epilepsy, Parkinson's disease or large territory stroke
• * Current substance abuse in accord with DSM V criteria
• * Significantly depressed (Geriatric Depression Scale \> 10)
• * Physical or psychological MRI contraindications, or likely unable to tolerate neuroimaging
• * Taking other medications known to affect serum sex hormone or gonadotropin concentrations such as estrogen and/or progesterone for hormone replacement therapy, goserelin or danazol
• * Presence of significant systemic illness likely to interfere with participation in or completion of the study or to affect study results such as cancer within 5 years (other than non-melanoma skin cancer), autoimmune disease, recent myocardial infarction, signs/symptoms of organ failure based on history, ECG, screening laboratory and/or physical exams
• * Receiving other investigational drugs within 30 days or 5 half-lives prior to randomization, whichever is longer